PRF Growth Factor Release
Conditions
Keywords
Alb-PRF, L-PRF, growth factor, e-PRF, degredation, PRF membrane, A-PRF+
Brief summary
Platelet-rich fibrin (PRF) is widely used in regenerative dentistry because of its autologous growth factor release and fibrin scaffold properties. Different PRF preparations may exhibit different biological characteristics that influence their clinical performance. This study aims to compare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) regarding cumulative growth factor release and fibrin degradation. Blood samples obtained from healthy volunteers will be processed to prepare all three PRF types. Growth factor release and fibrin degradation will be analyzed under standardized laboratory conditions.
Detailed description
Platelet-rich fibrin products have become increasingly popular in regenerative medicine because they provide a fibrin scaffold capable of releasing multiple growth factors over time. However, differences in centrifugation protocols and preparation techniques may significantly affect their biological properties. Albumin-PRF is a recently introduced modification that combines heat-denatured plasma proteins with injectable PRF to increase scaffold stability and prolong growth factor release. This study will compare Alb-PRF, A-PRF+, and L-PRF prepared from the same healthy volunteers. Cumulative release of VEGF, PDGF-BB, and TGF-β1 will be evaluated on Days 1, 3, 5, and 7 using ELISA. Resistance to enzymatic degradation will be assessed by measuring delta D-dimer concentrations following trypsin-EDTA exposure. The results are expected to improve understanding of the biological performance of different PRF formulations.
Interventions
BIOLOGICALAlbumin-Platelet Rich Fibrin (Alb-PRF)
Autologous Albumin-Platelet Rich Fibrin prepared from peripheral venous blood using the Alb-PRF protocol for evaluation of growth factor release and enzymatic degradation.
BIOLOGICALAdvanced Platelet-Rich Fibrin (A-PRF)
Autologous Advanced Platelet-Rich Fibrin+ prepared from peripheral venous blood using the A-PRF+ protocol for evaluation of growth factor release and enzymatic degradation.
BIOLOGICALLeukocyte-Platelet Rich Fibrin (L-PRF)
Autologous Leukocyte-Platelet Rich Fibrin prepared from peripheral venous blood using the L-PRF protocol for evaluation of growth factor release and enzymatic degradation.
Sponsors
Izmir Katip Celebi University
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)
Masking description
Samples were coded before laboratory analyses. The researcher performing the ELISA and D-dimer measurements was unaware of the PRF preparation assigned to each sample until the analyses were completed.
Intervention model description
Blood samples obtained from each healthy volunteer were used to prepare Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF). Growth factor release and fibrin degradation characteristics of the three PRF preparations were compared under standardized laboratory conditions.
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers aged 18 to 40 years * Male or female * Able and willing to provide written informed consent * Non-smokers * No history of systemic disease * No regular medication use * No use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months
Exclusion criteria
* Age younger than 18 years or older than 40 years * Smoking * Pregnancy or breastfeeding * History of any systemic disease * Regular medication use * Use of antibiotics, corticosteroids, or non-steroidal anti-inflammatory drugs within the previous 6 months * Refusal or inability to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| VEGF concentration released from PRF membranes | Day 1, Day 3, Day 5, and Day 7 | Quantitative assessment of VEGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA). |
| PDGF concentration released from PRF membranes | Day 1, Day 3, Day 5, and Day 7 | Quantitative assessment of PDGF released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA). |
| TGF-B concentration released from PRF membranes | Day 1, Day 3, Day 5, and Day 7 | Quantitative assessment of TGF-B released from Albumin-PRF (Alb-PRF), Advanced Platelet-Rich Fibrin+ (A-PRF+), and Leukocyte-Platelet Rich Fibrin (L-PRF) using enzyme-linked immunosorbent assay (ELISA). |
| Resistance to enzymatic degradation | 60 minutes and 120 minutes | Assessment of fibrin degradation by measuring D-dimer levels after enzymatic digestion of PRF preparations. |
Countries
Turkey (Türkiye)
Outcome results
None listed